Antiangiogenic, antitumoural and antimetastatic effects of two distamycin A derivatives with anti-HIV-1 Tat activity in a Kaposi's sarcoma- like murine model

Clinical and Experimental Metastasis

Volumn 17, Issue 7, 1999, Pages 575-582

  Possati, Laura ^b   Campioni, Diana ^c   Sola, Francesco ^a   Leone, Luciana ^c   Ferrante, Luigi ^c   Trabanelli, Cecilia ^c   Ciomei, Marina ^a   Montesi, Marco ^c   Rocchetti, Romina ^c   Talevi, Simona ^c   Bompadre, Stefano ^c   Caputo, Antonella ^c   Barbanti Brodano, Giuseppe ^c   Corallini, Alfredo ^c  

^a PFIZER INC   (United States)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c NONE

Author keywords

Angiogenesis; Distamycin A derivatives; HIV 1 Tat; Kaposi's sarcoma; Metastasis

Indexed keywords

7,7 [CARBONYL BIS[IMINO N METHYL 4,2 PYRROLECARBONYLIMINO (N METHYL 4,2 PYRROLE)CARBONYLIMINO]] BIS(1,3 NAPHTHALENE DISULFONATE); DISTAMYCIN A DERIVATIVE; MINOCYCLINE; PNU 153429; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HISTOPATHOLOGY; HUMAN IMMUNODEFICIENCY VIRUS 1; KAPOSI SARCOMA; MALE; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; TUMOR VASCULARIZATION;

EID: 20244373308     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006737029616     Document Type: Article

References (46)

1. 1. Folkman J. Tumor angiogenesis. Adv Cancer Res 1985; 43: 175-203.
2. 2. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6.
3. 3. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989; 339: 8-61.
4. 4. Bouck N. Tumor angiogenesis: The role of oncogenes and tumor suppressor genes. Cancer Cells 1990; 2: 179-85.
5. 5. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987; 235: 442-7.
6. 6. Rak J, Filmus J, Finkenzeller G et al. Oncogenes as inducers of tumor angiogenesis. Cancer Metast Rev 1995; 14: 263-77.
7. 7. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1995; 1: 27-31.
8. 8. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med 1995; 1: 149-53.
9. 9. Rak J, Kerbel RS. Treating cancer by inhibiting angiogenesis: new hopes and potential pitfalls. Cancer Metast Rev 1996; 15: 231-6.
10. 10. Varner JA, Cheresh DA. Tumor angiogenesis and the role of vascular cell integrin αvβ3. In De Vita VT, Hellman S, Rosenberg SA (eds): Important Advances in Oncology. Philadelphia: Lippincott-Raven Publishers 1990; pp. 69-87.
11. 11. Bicknell R, Harris AL. Anticancer strategies invoking the vasculature: vascular targeting and the inhibition of angiogenesis. Semin Cancer Biol 1992; 3: 399-407.
12. 12. Sipos EP, Tamargo RJ, Weingart JO, Brem H. Inhibition of tumor angiogenesis. Ann NY Acad Sci 1994; 732: 263-72.
13. 13. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998; 279: 377-80.
14. 14. Bohem T, Folkman J, Browder T, O'Reilly M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404-7.
15. 15. Hanahan D. A flanking attack on cancer. Nature Med 1998; 4: 13-4.
16. 16. Kerbel RS. A cancer therapy resistant to resistance. Nature 1997; 390: 335-6.
17. 17. Folkman J. Angiogenesis and its inhibitors. In De Vita VT, Hellman S, Rosenherg SA (eds): Important Advances in Oncology. Philadelphia: Lippincott-Raven Publishers 1985; pp. 42-62.
18. 18. Folkman J, Ingber D. Inhibition of angiogenesis. Semin Cancer Biol 1992; 3: 89-96.
19. 19. Teicher BA. A system approach to cancer therapy. Cancer Metast Rev 1996; 15: 247-72.
20. 20. Campioni D, Corallini A, Zauli G et al. HIV type 1 extracellular Tat protein stimulates growth and protects cells of BK virus/tat transgenic mice from apoptosis. AIDS Res Hum Retrov 1995; 11: 1039-18.
21. 21. Ensoli B, Barillari G, Salahuddin ZS et al. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature 1990; 345: 84-6.
22. 22. Milani D, Zauli G, Neri LM et al. Influence of the human immunodeficiency virus type 1 Tat protein on the proliferation and differentiation of PC12 rat pheochromocytoma cells. J Gen Virol 1993; 74: 2587-94.
23. 23. Viscidi RP, Mayur K, Lederman HM, Frankel AD. Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1. Science 1989; 246: 1606-8.
24. 24. Zauli G, Gibellini D, Milani D et al. Human immunodeficiency virus type 1 Tat protein protects lymphoid, epithelial, and neuronal cell lines from death by apoptosis. Cancer Res 1993; 53: 4481-5.
25. 25. Albini A, Fontanini G, Masiello L et al. Angiogenic potential in vivo by Kaposi's sarcoma cell-free supernatants and HIV-1 tat product: inhibition of KS-like lesions by tissue inhibitor of metalloproteinase 2. AIDS 1994; 8: 1237-44.
26. 26. Albini A, Barillari G, Benelli R et al. Tat, the human immunodeficiency virus type 1 regulatory protein, has angiogenic properties. Proc Natl Acad Sci USA 1995; 92: 4838-42.
27. 27. Barillari G, Buonaguro L, Fiorelli V et al. Effects of cytokines from activated immune cells on vascular cell growth and HIV-I gene expression. Implication for AIDS-Kaposi's sarcoma pathogenesis. J Immunol 1992; 149: 3727-34.
28. 28. Barillari G, Gendelman R, Gallo RC, Ensoli B. The Tat protein of human immunodeficiency virus type I, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RDG amino acid sequence. Proc Natl Acad Sci USA 1993; 90: 7941-5.
29. 29. Corallini A, Altavilla G, Pozzi L et al. Systemic expression of HIV-1 tat gene in transgenic mice induces endothelial proliferation and tumors of different histotypes. Cancer Res 1993; 53: 5569-75.
30. 30. Vogel J, Hinrichs SH, Reynolds RK et al. The HIV tat gene induces dermal lesions resembling Kaposi's sarcoma in transgenic mice. Nature 1988; 335: 606-11.
31. 31. Ensoli B, Gendelman R, Markham P et al. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature 1994; 371: 674-80.
32. 32. Corallini A, Campioni D, Rossi C et al. Promotion of tumor metastases and induction of angiogenesis by native HIV-1 Tat protein from BK virus/tat transgenic mice. AIDS 1996; 10: 701-10.
33. 33. Mariani M, Paio A, Ciomei M et al. In vitro activity of novel sulphonic derivatives of distamycin A. In Steiner R, Weisz PB, Langer R (eds). Angiogenesis: Key Principles-Science-Technology-Medicine. Basel: Birkhauser Verlag 1992: pp. 455-8.
34. 34. Sola F, Biasoli G, Pesenti F. et al. In vivo activity of novel sulphonic derivatives of distamycin A. In Steiner R, Weisz PB, Langer R (eds) Angiogenesis: Key Principles-Science-Technology-Medicine. Basel: Birkhauser Verlag 1992: pp. 459-462,
35. 35. Sola F, Farao M, Pesenti E et al. Antitumor activity of FCE26644 a new growth-factor complexing molecule. Cancer Chemother Pharmacol 1995; 36: 217-22.
36. 36. Sola F, Farao M, Ciomei M et al. FCE27266, a sulphonic distamycin derivative, inhibits experimental and spontaneous lung and liver metastasis. Invasion Metast 1995; 15: 222-31.
37. 37. Corallini A, Betti M, Rusnati M et al. Characterization of the effects of two polysulfonated distamycin A derivatives, PNU145156E and PNU153429, on HIV type 1 Tat protein. AIDS Res. Hum. Retrov 1998; 14: 1561-71.
38. 38. Tamargo RJ, Bok RA, Brem H. Angiogenesis inhibition by minocycline. Cancer Res 1993; 53: 5569-75.
39. 39. Bassukas ID. Comparative gompertzian analysis of alterations of tumor growth patterns. Cancer Res 1994; 54: 4385-92.
40. 40. Bassukas ID, Hofmockel G, Tsatalpas P et al. Prognostic relevance of the intrinsic growth deceleration of the first passage xenografts of human renal cell carcinomas. Cancer 1996; 78: 2170-2.
41. 41. Fuchshuber P, Günther M, Feaux De Lacroix W, Fisher R. A mathematical model for metastatic growth illustrated by in vivo and in vitro growth of a transplantable mammary carcinoma in mice. Anticancer Res 1986; 6: 819-28.
42. 42. Armitage P. Statistical Methods in Medical Research. New York 1971; Wiley.
43. 43. Smith KA, Hill SA, Begg AC, Denekamp J. Validation of the fluorescent dye Hoechst 33342 as a vascular space marker in tumours. Br J Cancer 1988; 57: 247-53.
44. 44. Rusnati M, Coltrini D, Campioni D et al. Upregulation of urokinase-type plasminogen activator by endogenous and exogenous HIV-1 Tat protein in tumour cell lines derived from BK virus/tat-transgenic mice. AIDS 1997; 11: 727-36.
45. 45. Rusnati M, Tulipano G, Urbinati C et al. The basic domain in HIV-1 Tat protein as a target for polysulfonated heparin-mimicking extracellular Tat antagonists. J Biol Chem 1988; 273: 16027-37.
46. 46. Bompadre S, Ferrante L, Leone L et al. Column-switching high-performance liquid chromatographic assay for minocycline of nude mice serum. J Liq Chrom & Rel Technol 1997; 20: 1257-67.